Jump to content

Letolizumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WildCation (talk | contribs) at 12:43, 17 April 2018 (Chembox edits: Set CSID to none). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Letolizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized (from mouse)
Targettumor necrosis factor related activation protein
Clinical data
Other namesBMS-986004
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC1734H2688N466O538S10
Molar mass39.0 g/mol g·mol−1

Letolizumab (INN[1]) (BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

This drug was developed by Bristol-Myers Squibb.[2]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Letolizumab&oldid=836884330"